Johnson & Johnson has stopped its Phase 3 SunRISe-2 trial for TAR-200, a potential treatment for muscle-invasive urothelial carcinoma (MIBC), after an independent review board determined it wasn’t outperforming standard chemotherapy. Despite this setback, the company remains confident in the overall potential of the TARIS platform and its future prospects in bladder cancer treatment.